The economics of direct-to-consumer advertising of prescription-only drugs: Prescribed to improve consumer welfare?

Journal of Health Services Research and Policy

Volumn 8, Issue 4, 2003, Pages 237-244

  Morgan, Steven G ^a   Mintzes, Barbara ^a   Barer, Morris ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; UNCLASSIFIED DRUG;

ADVERTISING;

ADVERTIZING; ALTERNATIVE MEDICINE; CONSUMER; DRUG INFORMATION; DRUG MARKETING; EXPERIENCE; MARKET; PERSUASIVE COMMUNICATION; PHARMACOECONOMICS; PHYSICIAN; PREDICTION; PRESCRIPTION; PRESCRIPTION DRUG; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THEORY;

ADVERTISING; COMMERCE; DRUG INDUSTRY; DRUG INFORMATION SERVICES; HUMANS; MASS MEDIA; PATIENT EDUCATION; PATIENT PARTICIPATION; PERSUASIVE COMMUNICATION; PHYSICIAN-PATIENT RELATIONS; PRESCRIPTIONS, DRUG; SOCIAL WELFARE; UNITED STATES;

EID: 0141928732     PISSN: 13558196     EISSN: None     Source Type: Journal    
DOI: 10.1258/135581903322403317     Document Type: Review

References (38)

1. Temin P. Taking your medicine: drug regulation in the United States. Cambridge, MA: Harvard University Press, 1980
2. Lyles A. Direct marketing of pharmaceuticals to consumers. Annual Review of Public Health 2002; 23: 73-91
3. Rice T. The economics of health reconsidered. Chicago: Health Administration Press, 1998
4. Kaldor N. The economic aspects of advertising. Review of Economic Studies 1950; 18: 1-27
5. Dixit A, Norman V. Advertising and welfare. Bell Journal of Economics 1976; 9: 1-17
6. Stigler GJ. The economics of information. Journal of Political Economy 1961; 69: 213-225
7. Nelson P. Information and consumer behavior. Journal of Political Economy 1970; 78: 311-329
8. Nelson P. Advertising as information. Journal of Political Economy 1974; 82: 729-754
9. Becker GS, Murphy KM. A simple theory of advertising as a good or bad. Quarterly Journal of Economics 1993; 108: 941-964
10. Kotowitz YK, Mathewson F. Informative advertising and welfare. American Economic Review 1979; 69: 284-294
11. Morgan S, Barer M, Evans R. Health economists meet the fourth tempter: drug dependency and scientific discourse. Health Economics 2000; 9: 659-667
12. Mintzes B. Blurring the boundaries: new trends in drug promotion. Amsterdam: Health Action International, 1998
13. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000; 283: 373-380
14. Sullivan P. Freebies to MDs targeted as drug industry starts publicizing CME fines. Canadian Medical Association Journal 2000; 163: 749
15. Akerlof G. The market for 'lemons': qualitative uncertainty and the market mechanism. Quarterly Journal of Economics 1970; 89: 488-500
16. Findlay SD. Prescription drugs and mass media advertising. Washington, DC: National Institute of Health Care Management, 2000
17. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995; 273: 1296-1298
18. Visite médicale: le bilan accablant du reseau d'observation de la revue prescrire. Revue Prescrire 1999; 19: 226-231
19. Lexchin J. What information do physicians receive from pharmaceutical representatives. Canadian Family Physician 1997; 73: 941-945
20. Ubel PA, Arnold RM, Gramelspacher GP, Hoppe RB, Landefeld CS, Levinson W et al. Acceptance of external funds by physician organizations: issues and policy options. Journal of General Internal Medicine 1995; 10: 624-630
21. Sheldon TA, Smith GD. Consensus conferences as drug promotion. Lancet 1993; 341: 499
22. Springarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? Academic Medicine 1996; 71: 86-88
23. Herxheimer A, Collier J. Promotion by the British pharmaceutical industry, 1983-8: a critical analysis of self regulation. BMJ 1990; 300: 307-311
24. Hagerman M. Prescription drug advertising in Canada: an assessment. Presentation. Ottawa: Deputy Ministers of Health Subcommittees on Pharmaceutical Policy Issues, 1992
25. Kline S. Prescription drug advertising. Communicating risk, benefit, and cost of pharmaceuticals. In: Invitational Workshop on Drug Advertising, 24 February 1992. Ottawa: Canadian Public Health Association, 1992
26. Lexchin J, Holbrook A. Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. CMAJ 1994; 151: 47-54
27. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts' assessments. Annals of Internal Medicine 1992; 116: 912-919
28. Loke TW, Koh FC, Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Medical Journal of Australia 2002; 177: 291-293
29. Herxheimer A, Lundborg CS, Westerholm B. Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards. International Journal of Health Services 1993; 23: 161-172
30. Drug advertising: is this good medicine? Consumer Reports 1996; 61: 62-63
31. Roth MS. Patterns in direct-to-consumer prescription drug print advertising and their public policy implications. Journal of Public Policy and Marketing 1996; 15: 63-75
32. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising, 1989-1998. A content analysis of conditions, targets, inducements, and appeals. Journal of Family Practice 2000; 49: 329-335
33. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet 2001; 358: 1141-1146
34. Ostrove N. Prescription drug issues. FDCH Congressional Testimony. Washington, DC: Committee on Commerce, Science and Transportation, 2001: 24
35. Pratt P. Assessment of regulatory compliance for medicines advertised direct-to-consumer. Summary report. Wellington, New Zealand: Medsafe, 2000
36. Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 2002;324:278-279
37. Zabor JD, Wyman F. Increasing ROI through DTC-driven web site visits. DTC Perspectives 2002; June-July: 34-40
38. Promotion of prescription drugs: public health or private profit? Policy report. London: Consumers' Association, 2001